Saturday 17 October 2026
Export STIM’s income statement to Excel — free account
Neuronetics, Inc.
STIM Healthcare Medical Devices
Neuronetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $149.2 million, up 99.2% from fiscal 2024. In the quarter to June 2026, revenue grew 9.08%, EPS grew 66.7%, free cash flow grew 62.1% and total debt rose 10.8%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
1.89
0.06
−3.08%
Follow STIM
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.61 | 0.67 | 0.61 | 1.41 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(94.31) | (10.71) | 100.23 | (234.08) | |
P/B ratio |
4.39 | 5.91 | 3.47 | 5.86 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.94 | 1.03 | 0.91 | 1.76 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(14.07) | (12.23) | (6.68) | (7.64) | |
EV/FCF |
(12.92) | (11.55) | (6.43) | (7.48) | |
Quick Ratio |
1.46 | 1.25 | 1.68 | 1.86 | |
Current Ratio |
1.88 | 1.67 | 2.02 | 2.24 | |
Net Debt/EBITDA |
(47.07) | (5.10) | (7.35) | (4.82) | |
Debt/Assets |
46.77% | 48.87% | 46.49% | 45.15% | |
Debt/Equity |
2.84 | 3.59 | 2.51 | 2.09 | |
Asset Turnover |
1.17 | 1.13 | 1.06 | 1.18 | |
Operating CF/Net income |
0.29 | 0.87 | (0.13) | 0.09 | |
Capex/Depreciation |
(0.57) | (0.23) | (0.28) | (0.13) | |
Interest Coverage |
(0.71) | (3.97) | (2.18) | (3.32) | |
Research and Development Expense of Revenue |
3.21% | 3.96% | 3.99% | 4.03% | |
Selling, General and Administrative Expense of Revenue |
51.45% | 69.03% | 60.04% | 61.47% | |
Intangible Assets out of Total Assets |
0.31 | 0.33 | 0.30 | 0.28 | |
Share Based Compensation of Revenue |
1.66% | 4.87% | 5.22% | 3.78% | |
Graham Net Nets |
(0.60) | (0.61) | (0.59) | (0.27) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(33.85%) | (37.24%) | (42.75%) | (30.04%) | |
Free Cash Flow Yield |
(11.81%) | (13.43%) | (23.27%) | (16.63%) | |
Revenue per Share |
0.57 | 0.50 | 0.63 | 0.55 | |
Operating CF per Share |
(0.01) | (0.14) | 0.01 | (0.01) | |
Capex per Share |
(0.01) | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.02) | (0.14) | 0.01 | (0.01) | |
Cash per Share |
0.34 | 0.28 | 0.52 | 0.51 | |
Shareholders Equity per Share |
0.30 | 0.25 | 0.40 | 0.47 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.30 | 0.25 | 0.40 | 0.47 | |
Free Cash Flow |
(1.42) | (9.59) | 0.69 | (0.90) | |
Working Capital |
24.92 | 18.89 | 31.03 | 35.95 | |
Capital Expenditures |
(0.42) | (0.17) | (0.22) | (0.11) | |
Net Current Asset Value |
(56.66) | (61.20) | (53.76) | (49.22) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
21.46 | 21.55 | 20.59 | 19.24 | |
Average Payables |
11.07 | 9.96 | 10.91 | 7.43 | |
Average Inventory |
5.22 | 4.39 | 4.29 | 4.64 | |
Average Assets |
133.09 | 133.71 | 141.23 | 109.79 | |
Average Common Equity |
26.57 | 28.30 | 29.02 | 20.37 |
Columns are period end dates